nVerses Capital’s PTC Therapeutics PTCT Stock Holding History

nVerses Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,000	Closed	-$58.2K	–	1165
2024 Q1	$58.2K	Buy	+2,000	New	+$56K	0.14%	256

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

nVerses Capital's PTCT Position: Q2 2024 in Review

nVerses Capital sold out of PTC Therapeutics (PTCT) in Q2 2024, closing a stake of 2,000 shares — an estimated $58.2K sold.

nVerses Capital first reported a position in PTCT in Q1 2024 and held it in 1 quarter. The position peaked at $58.2K in Q1 2024. 198 funds tracked by Wall St. Rank hold PTCT as of Q2 2024.

nVerses Capital reported no remaining PTC Therapeutics position as of Q2 2024 after selling out during the quarter.
nVerses Capital sold 2,000 PTC Therapeutics shares in Q2 2024, an estimated $58.2K.
nVerses Capital first reported a position in PTC Therapeutics in Q1 2024 and held it in 1 quarter.
nVerses Capital's PTC Therapeutics position peaked at $58.2K in Q1 2024.
198 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2024.

Based on nVerses Capital's 13F filing for Q2 2024, filed 31 Jul 2024.